Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE
    • Publication Information:
      Publication: Berlin : Springer Verlag
      Original Publication: Berlin, New York, Springer International.
    • Subject Terms:
      Adenocarcinoma, Mucinous/*drug therapy ; Antineoplastic Combined Chemotherapy Protocols/*administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/*pharmacokinetics ; Breast Neoplasms/*drug therapy ; Carcinoma, Ductal, Breast/*drug therapy ; Carcinoma, Lobular/*drug therapy; Adenocarcinoma, Mucinous/secondary ; Administration, Oral ; Adolescent ; Adult ; Aged ; Breast Neoplasms/pathology ; Carcinoma, Ductal, Breast/secondary ; Carcinoma, Lobular/secondary ; China ; Epirubicin/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Injections, Intravenous ; Maximum Tolerated Dose ; Middle Aged ; Neoplasm Invasiveness ; Prognosis ; Prospective Studies ; Tissue Distribution ; Vinorelbine/administration & dosage ; Young Adult
    • Abstract:
      Oral VRL offers easier administration, better quality of life, and cost saving. This study aimed to evaluate the treatment efficacy in terms of tumor response of the two formulations of vinorelbine (VRL, oral and IV) in combination with epirubicin (EPI); and the effect of EPI co-administration on VRL pharmacokinetics (PK) in Chinese patients with metastatic breast cancer (MBC) using a phase 2, open label, randomized trial. Patients were aged 18-70 years, had histologically confirmed MBC, Karnofsky Performance Status ≥ 70%, and life expectancy ≥ 12 weeks. The treatment consisted of 6 cycles of 3 weeks each. VRL dose was: (Oral-VRL) 60 mg/m 2 for cycle 1, 80 mg/m 2 for cycles 2-6, and (IV-VRL) 25 mg/m 2 for cycle 1 and 30 mg/m 2 for cycles 2-6. EPI dose of 75 mg/m 2 was given on day 1 in both arms for all cycles. 133 patients were enrolled: 66 in Oral-VRL and 67 in IV-VRL arms. The median age for Oral-VRL and IV-VRL arms was 48.4 and 50.0 years, respectively. Objective response rates were 50.0% (95% CI 37.4-62.6%) for Oral-VRL and 53.7% (95% CI 41.1-66.0%) for IV-VRL. Both treatment arms met the efficacy objective target of at least 31 responses, demonstrating efficacy as first-line treatment for MBC. Similar blood PK profiles, exposures, and VRL clearance were observed between VRL + EPI vs VRL-only modalities for both arms. Oral VRL is comparable to IV VRL and an effective first-line treatment for Chinese patients with MBC. The activity of VRL + EPI combination is unaltered when VRL is given orally at recommended doses.
    • References:
      Br J Cancer. 2005 Jun 6;92(11):1989-96. (PMID: 15928659)
      J Clin Oncol. 2002 Jun 1;20(11):2689-94. (PMID: 12039931)
      J Clin Oncol. 1995 Nov;13(11):2722-30. (PMID: 7595730)
      J Nucl Cardiol. 1997 Nov-Dec;4(6):494-501. (PMID: 9456189)
      Chemotherapy. 2017;62(1):71-79. (PMID: 27648841)
      Cancer Res. 2001 Oct 1;61(19):7136-41. (PMID: 11585746)
      Curr Breast Cancer Rep. 2013 Mar 1;5(1):42-50. (PMID: 23440080)
      Eur J Heart Fail. 2018 Oct;20(10):1447-1453. (PMID: 29493047)
      J Clin Oncol. 2004 Jun 15;22(12):2313-20. (PMID: 15197192)
      Clin Cancer Res. 2001 Mar;7(3):517-23. (PMID: 11297242)
      Chemotherapy. 2010;56(4):340-7. (PMID: 20720418)
      Eur J Oncol Nurs. 2004;8 Suppl 1:S54-62. (PMID: 15341882)
      Curr Drug Saf. 2011 Jul;6(3):185-93. (PMID: 22122393)
      J Clin Oncol. 2003 Jan 1;21(1):35-40. (PMID: 12506167)
      Curr Med Res Opin. 2016 Nov;32(11):1807-1812. (PMID: 27388853)
      Cancer Chemother Pharmacol. 2007 Aug;60(3):407-13. (PMID: 17541591)
      J Clin Oncol. 1994 Feb;12(2):336-41. (PMID: 8113840)
      Clin Breast Cancer. 2018 Feb;18(1):e41-e47. (PMID: 28666812)
      Ann Oncol. 2012 Oct;23 Suppl 7:vii11-9. (PMID: 22997442)
      J Clin Oncol. 1993 Jul;11(7):1245-52. (PMID: 8315421)
      J Clin Oncol. 2014 Oct 10;32(29):3307-29. (PMID: 25185096)
      Lancet Oncol. 2014 Jun;15(7):e279-89. (PMID: 24872111)
      CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. (PMID: 26808342)
      Ann Oncol. 1994 Nov;5(9):854-7. (PMID: 7848890)
      Am J Clin Oncol. 1995 Oct;18(5):392-6. (PMID: 7572754)
      Biometrics. 1982 Mar;38(1):143-51. (PMID: 7082756)
      Eur J Cancer. 2010 Mar;46(4):703-12. (PMID: 20034784)
      Asian Pac J Cancer Prev. 2010;11(4):1115-8. (PMID: 21133634)
      Cancer Treat Rev. 2010 Dec;36(8):595-605. (PMID: 20570443)
      Tumori. 2007 Nov-Dec;93(6):544-9. (PMID: 18338487)
      J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. (PMID: 10655437)
      Ann Oncol. 1999 Aug;10(8):937-42. (PMID: 10509155)
      Breast Cancer Res Treat. 1996;39(3):285-91. (PMID: 8877008)
      BMC Cancer. 2009 Oct 21;9:375. (PMID: 19845944)
      Br J Cancer. 1994 Nov;70(5):990-3. (PMID: 7947109)
      Ann Transl Med. 2018 Jul;6(14):284. (PMID: 30105234)
    • Contributed Indexing:
      Keywords: Chinese patients; Epirubicin; Intravenous vinorelbine; Metastatic breast cancer; Oral vinorelbine
    • Accession Number:
      3Z8479ZZ5X (Epirubicin)
      Q6C979R91Y (Vinorelbine)
    • Publication Date:
      Date Created: 20191216 Date Completed: 20200629 Latest Revision: 20200629
    • Publication Date:
      20231215
    • Accession Number:
      PMC6994442
    • Accession Number:
      10.1007/s00280-019-04000-3
    • Accession Number:
      31838561